glp-1 drugs and muscle loss Loss: Semaglutide, Tirzepatide & Lean Mass Balancing weight and muscle loss
Description
95% CI 0.310.50), MACEs (aHR 0.66
pooling data for lixisenatide (Adlyxin, Sanofi), liraglutide (Victoza,
Deal Snapshot: Novo is partnering with Ascendis on less frequently dosed drugs for metabolic diseases, committing up to $285m for a lead program, a once-monthly GLP-1 receptor agonist.
A new short-term CMS demonstration changes that for 18 months.
A study of health insurance claims found a 44% reduction in hospitalizations for GLP-1 users
